The Patent Finder

Gliapharm S.A.

7 patents currently held · Updated Nov 15, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Mar 2033
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Aug 16, 2027
    The maintenance fee for 4-OXO-2-Pentenoic Acid and Brain Health (US 9,259,404) comes due Aug 16, 2027. Unpaid by Feb 16, 2028, it lapses early.
  • 1 fee due Sep 12, 2027
    The maintenance fee for Isoquinoline Derivatives for Use in Treating GLUT1 Deficiency Syndrome (US 11,925,632) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 7 of 7

PatentTitleStatus Expires Confidence
US 9,259,4044-OXO-2-Pentenoic Acid and Brain Health
In force
 · High confidence
In forceHigh confidence
US 11,339,111Polyketide Compound and Derivatives Thereof for Use in the Prevention and Treatment of a Neurological Disorder
In force
 · High confidence
In forceHigh confidence
US 12,310,967Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
In force
 · From the USPTO record
In forceFrom the USPTO record
US 12,274,703Compositions and methods of treatment for neurological disorders comprising a dementia
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,510,890Meroterpenoid Compounds for Use in the Prevention and Treatment of a Neurological Disorder
In force
 · High confidence
In forceHigh confidence
US 11,925,632Isoquinoline Derivatives for Use in Treating GLUT1 Deficiency Syndrome
In force
 · High confidence
In forceHigh confidence
US 12,433,892Compositions and methods of treatment for neurological disorders comprising depression
In force
 · From the USPTO record
In forceFrom the USPTO record

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

1 abandoned · 2 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited